Want to see RLAY full AI Analyst Report?
RLAY Stock Chart & Stats
$20.57
-$0.65(-3.40%)
At close: 4:00 PM EDT
$20.57
-$0.65(-3.40%)
Day’s Range― - ―
52-Week Range$3.50 - $21.27
Previous Close$18.19
Volume2.04M
Average Volume (3M)3.71M
Market Cap
$4.33B
Enterprise Value$2.92K
Total Cash (Recent Filing)$910.93M
Total Debt (Recent Filing)$30.66M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Nov 11, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding219,141,630
10 Day Avg. Volume2,093,897
30 Day Avg. Volume3,714,105
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.56
Price to Sales (P/S)94.54
P/FCF Ratio-6.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$27.63Price Target Upside34.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.6
Revenue Forecast (FY)$10.66M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low leverage provides durable financial flexibility for a clinical-stage biotech that requires long R&D cycles. Low debt reduces near-term default and interest constraints, allowing management to prioritize pipeline funding and strategic partnerships without immediate refinancing pressure.
Proprietary Computational Drug-discovery PlatformA differentiated platform focused on protein motion offers a structural competitive advantage that can generate multiple programs and licensing opportunities over time. Platform-driven discovery can lower cost/time per candidate and supports repeatable pipeline creation and partner collaborations.
Promising Phase 2 Zovegalisib DataConvincing early efficacy and tolerability in a rare-disease indication materially de-risks the zovegalisib program and informs dose strategy. Durable impact: success in a genetically defined, underserved indication can broaden revenue potential beyond oncology and strengthen partnership/commercial prospects.
Bears Say
High Cash Burn / Negative Cash FlowSustained negative operating and free cash flow indicates the core business cannot self-fund development. Over a multi-month horizon this necessitates frequent external financing, constraining strategic optionality and increasing risk of shareholder dilution or program slowdowns if markets tighten.
Sustained Unprofitability And Negative Gross ProfitDeep, ongoing losses and negative gross profit show current operations consume more resources than they generate. Structurally, this weakens the path to scalable commercial margins and heightens reliance on milestones/partnerships; prolonged losses can erode equity and limit reinvestment.
Expanded Equity Issuance Capacity / Dilution RiskMaterial increases in authorized shares and ATM capacity signal recurring reliance on equity markets to fund operations. Over several months this elevates dilution risk for existing holders, can change capital structure dynamics, and may pressure incentives and per-share economics as R&D continues to consume cash.
Relay Therapeutics News
RLAY FAQ
What was Relay Therapeutics’s price range in the past 12 months?
Relay Therapeutics lowest stock price was $3.50 and its highest was $21.27 in the past 12 months.
What is Relay Therapeutics’s market cap?
Relay Therapeutics’s market cap is $4.33B.
When is Relay Therapeutics’s upcoming earnings report date?
Relay Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 76 days.
How were Relay Therapeutics’s earnings last quarter?
Relay Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.019.
Is Relay Therapeutics overvalued?
According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued.
Does Relay Therapeutics pay dividends?
Relay Therapeutics does not currently pay dividends.
What is Relay Therapeutics’s EPS estimate?
Relay Therapeutics’s EPS estimate is -0.4.
How many shares outstanding does Relay Therapeutics have?
Relay Therapeutics has 219,141,630 shares outstanding.
What happened to Relay Therapeutics’s price movement after its last earnings report?
Relay Therapeutics reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went up 0.101%.
Which hedge fund is a major shareholder of Relay Therapeutics?
Currently, no hedge funds are holding shares in RLAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relay Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.63 (34.30% Upside)
$27.63 (34.30% Upside)
Blogger Sentiment
Neutral
RLAY Sentiment 57%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 7.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $82.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 9.2%
Last 30 Days ▼ 9.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
401.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
32.74%
Trailing 12-Months
Company Description
Relay Therapeutics
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
RLAY Stock 12 Month Forecast
Average Price Target
$27.63
▲(34.30% Upside)
Technical Analysis
Ownership Overview
1.59% Insiders
11.21% Mutual Funds
60.03% Other Institutional Investors
12.49% Public Companies and Individual Investors